BB-Cl-Amidine
Names
[ CAS No. ]:
1802637-39-3
[ Name ]:
BB-Cl-Amidine
[Synonym ]:
N-{(1S)-1-(1H-Benzimidazol-2-yl)-4-[(2-chloroethanimidoyl)amino]butyl}-4-biphenylcarboxamide
[1,1'-Biphenyl]-4-carboxamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-
Biological Activity
[Description]:
BB-Cl-Amidine is a peptidylarginine deminase (PAD) inhibitor.
[Related Catalog]:
[Target]
[In Vitro]
Cl-amidine and BB-Cl-amidine show similar in vitro potencies and selectivities; however, the cellular potency of BB-Cl-amidine is increased by more than 20-fold, evidenced by decreased EC50 values obtained from viability studies with U2OS osteosarcoma cells (8.8±0.6 μM vs >200 μM for Cl-amidine). Cl-amidine and BB-Cl-amidine significantly inhibit NET formation by MRL/lpr neutrophils[1].
[In Vivo]
Treatment with BB-Cl-amidine subtly reduces splenomegaly in MRL/lpr mice, while there is a trend towards increased circulating levels of anti-NET antibodies with PAD inhibitor treatment. However, neither PAD inhibitor affected body weight or total IgG levels. Indeed, treatment with both Cl-amidine and BB-Cl-amidine significantly improves endothelium-dependent vasorelaxation. The BB-Cl-amidine group also shows a strong trend towards downregulation of IRGs. Treatment with either Cl-amidine or BB-Cl-amidine significantly improves muzzle alopecia, in many cases preventing it entirely[1].
[Animal admin]
Mice[1] MRL/lpr mice are treated with either Cl-amidine (Cl-am; 10 mg/kg/day) or BB-Cl-amidine (BB-Cl-am; 1 mg/kg/day) by daily subcutaneous injection from 8 to 14 weeks of age[1].
[References]
[Related Small Molecules]
Chemical & Physical Properties
[ Density]:
1.3±0.1 g/cm3
[ Molecular Formula ]:
C26H26ClN5O
[ Molecular Weight ]:
459.970
[ Exact Mass ]:
459.182587
[ LogP ]:
3.86
[ Index of Refraction ]:
1.655
[ Storage condition ]:
2-8℃